Status:
COMPLETED
A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers
Lead Sponsor:
Merrimack Pharmaceuticals
Collaborating Sponsors:
Sanofi
Conditions:
Colorectal Cancer
Squamous Cell Head and Neck Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study was to evaluate the safety and tolerability of escalating doses of the MM-121 plus cetuximab and the MM-121 plus cetuximab plus irinotecan combination.
Detailed Description
This study was a Phase 1 and pharmacologic dose-escalation trial of MM-121 plus cetuximab plus irinotecan. The study assessed the safety, tolerability, and pharmacokinetics of MM-121, cetuximab and ir...
Eligibility Criteria
Inclusion
- No standard options remaining
- Adequate liver and kidney functions
- 18 years of age or above
Exclusion
- History of any secondary active cancer in the last 3 years.
- Pregnant or breast feeding
- History of severe allergic reactions or contraindications to cetuximab or irinotecan
Key Trial Info
Start Date :
October 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2014
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT01451632
Start Date
October 1 2011
End Date
June 1 2014
Last Update
September 8 2016
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
San Francisco, California, United States, 94115
2
Boston, Massachusetts, United States, 02115
3
Chapel Hill, North Carolina, United States, 27599
4
Salt Lake City, Utah, United States, 84112